Lawrencef Eichenfield News Today

Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD), according to a study published online May 2 in the American Journal of Clinical Dermatology.

Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.

Researchers integrated data from two pivotal trials and a long-term extension study.

In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.

These new data highlight the importance of larger trials to evaluate the persistence of this treatment’s efficacy and safety seen here.

Strong efficacy data for new class of agents in AD, but some apprehension over safety warnings

There were no significant safety signals in the younger pediatric population, and no treatment-emergent adverse events suggestive of systemic JAK inhibition, Dr Lawrence Eichenfield said.

Longer median time of flare-free maintenance, greater number of flare-free days, and lower mean number of flares.

WEDNESDAY, June 28, 2023 (HealthDay News) -- Crisaborole is effective as a long-term maintenance therapy for pediatric and adult patients with mild-to-moderate atopic dermatitis (AD), according to a study published

WEDNESDAY, June 28, 2023 (HealthDay News) -- Crisaborole is effective as a long-term maintenance therapy for pediatric and adult patients with mild-to-moderate atopic dermatitis (AD), according to a study published